Pfizer Strikes $43bn Deal for Cancer Drug Innovator Seagen
The pharmaceutical giant Pfizer has struck a $43bn deal for biotech company Seagen to add innovative targeted therapies to its portfolio of cancer treatments.
Monday’s deal is Pfizer’s biggest in a string of acquisitions after a cash windfall from its COVID-19 vaccine and pill. The acquisition will add four approved cancer therapies with combined sales of nearly $2bn in 2022.
Pfizer said Monday that it will pay $229 in cash for each share of Seagen. It then plans to let the biotech drug developer “continue innovating” except with more resources than it would have alone, Pfizer Chairman and CEO Albert Bourla told analysts.
“We are not buying the golden eggs,” he said. “We are acquiring the goose that is laying the golden eggs.”
Bothell, Washington-based Seagen specialises in working with antibody drug conjugate, or ADC, technology. Its key products use lab-made proteins called monoclonal antibodies that seek out cancer cells to help deliver a cancer-killing drug while sparing surrounding tissue.
Cancer treatments are a priority for Pfizer. They brought in $12bn in revenue for the drugmaker last year. But Pfizer has marketed only a couple first-generation ADC treatments, a spokeswoman said.
Seagen has four treatments on the market. It also has a pipeline of drugs under development that include potential treatments for a form of lung cancer and advanced breast cancer.
“We think this really changes dramatically the oncology presence of Pfizer, makes it one of a kind,” Bourla said.
Seagen’s top seller, Adcetris, treats lymph system cancers. It had $839m in sales last year, a 19 percent increase over the previous year.
Read Also:
Seagen also has a deal with Pfizer’s Array BioPharma to develop, make and sell the breast and colorectal cancer treatment Tukysa. It brought in $353m in sales for Seagen last year.
Read Also: Pfizer, BioNTech Vaccine 73.2% Effective In Children Under 5
The company, which changed its name from Seattle Genetics in 2020, saw total revenue grow about 25 percent last year to nearly $2bn. Seagen also shaved its loss to $610m from $674m in 2021.
The drug developer predicts about $2.2bn in sales for this year.
Pfizer booked about $100bn in total revenue last year and has been flush with cash thanks to sales of its COVID-19 vaccine Comirnaty and treatment Paxlovid.
Bourla said this year that the company planned to use its “extraordinary firepower” to buy products that will deliver $25bn in incremental revenue by 2030.
The deal announced Monday and some previous acquisitions will help Pfizer account for most of that. But Bourla emphasised on Monday that the company expects Seagen’s contributions to extend beyond the end of the decade.
New York-based Pfizer has already spent $11.6bn on migraine treatment developer Biohaven Pharmaceutical. It also spent $5.4bn on sickle cell disease treatment maker Global Blood Therapeutics and bought Arena Pharmaceuticals for another $6.7bn.
The drugmaker needs more revenue sources in part because it faces the expiration of patents protecting drugs like its breast cancer treatment Ibrance from cheaper competition in the coming years.
Pfizer said Monday that it will pay for Seagen mostly through $31bn in new, long-term debt.
Both companies’ boards have unanimously approved the deal. But regulators still need to look at it, and Seagen shareholders will have to approve it.
The companies expect to complete the transaction in late 2023 or early 2024.
Shares of Pfizer rose 2 percent to $40.26 after markets opened on Monday while Seagen’s stock soared more than 15 percent to nearly $200. Broader indexes edged up slightly.
